GlassScriptPhysician profile
Haleh Pazwash
NPI 1902856099
$126,390.20
in general payments reported to CMS, 2019-2025
43 companies · $26K in 2025
The $26K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $4,109 · 2021: $9,367 · 2022: $19K · 2023: $22K · 2024: $33K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $11K · Food and Beverage: $8,920 · Consulting Fee: $4,147 · Travel and Lodging: $3,396 · Honoraria: $2,500 · Education: $44.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,480.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,200.00 |
| Food and Beverage | $8,920.15 |
| Consulting Fee | $4,147.00 |
| Travel and Lodging | $3,396.17 |
| Honoraria | $2,500.00 |
| Education | $44.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $31,041.78 | 2023-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25,445.60 | 2019-2025 | Trulance, Xifaxan |
| Abbvie INC. | $24,633.59 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $21,419.59 | 2019-2024 | Linzess |
| Allergan, INC. | $13,556.33 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $3,141.00 | 2025 | Dupixent |
| Celltrion USA INC. | $1,050.04 | 2024-2025 | Zymfentra |
| Celgene Corporation | $754.20 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $744.12 | 2021-2025 | Sucraid, Sucraid |
| Pfizer INC. | $676.35 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $585.82 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $466.53 | 2019-2025 | Stelara, Tremfya, Simponi |
| Ardelyx, INC. | $376.18 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $208.43 | 2019-2025 | Rebyota |
| Vivus LLC | $197.73 | 2024-2025 | Qsymia, Pancreaze |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haleh Pazwash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.